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Trends in genetic patent applications: the
commercialization of academic intellectual property
Jannigje G Kers1,2, Elco Van Burg3, Tom Stoop4 and Martina C Cornel*,2,5
We studied trends in genetic patent applications in order to identify the trends in the commercialization of research findings
in genetics. To define genetic patent applications, the European version (ECLA) of the International Patent Classification (IPC)
codes was used. Genetic patent applications data from the PATSTAT database from 1990 until 2009 were analyzed for time
trends and regional distribution. Overall, the number of patent applications has been growing. In 2009, 152000 patent
applications were submitted under the Patent Cooperation Treaty (PCT) and within the EP (European Patent) system of the
European Patent Office (EPO). The number of genetic patent applications increased until a peak was reached in the year 2000,
with 48000 applications, after which it declined by almost 50%. Continents show different patterns over time, with the global
peak in 2000 mainly explained by the USA and Europe, while Asia shows a stable number of 41000 per year. Nine countries
together account for 98.9% of the total number of genetic patent applications. In The Netherlands, 26.7% of the genetic
patent applications originate from public research institutions. After the year 2000, the number of genetic patent applications
dropped significantly. Academic leadership and policy as well as patent regulations seem to have an important role in the trend
differences. The ongoing investment in genetic research in the past decade is not reflected by an increase of patent
applications.
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INTRODUCTION
For many years, protecting and commercializing intellectual property
(IP) through patents on human materials like polypeptides, genes,
nucleotides and living organisms has been a point for debate.1–5
Patents may have a role in the translation of genetic research in
commercial applications.6 Some researchers argue that protecting a
discovery is essential to increase innovation activities and also to
increase the chances that investments in research and development
will be profitable.7 Protecting a technological innovation is done by
applying for a patent on the invention. A patent forms an IP right
that gives the owner the exclusive rights to the commercial use of a
technical invention for a maximum of 20 years.1,8
Information about patent applications can be used to derive trends
in research areas and to identify new developments at an early stage.9
Today, patent data have become more readily available for research
purposes due to the increase in searchable public online databases,10
thereby enabling trends in genetic patent applications (GPAs) to be
analyzed. As patents give an owner the right to exclude others from
using the invention, they are often considered as a key indicator for
research and innovation output.11–13 Patented inventions are often
licensed to established companies and venture-capital-backed start-
ups that create jobs for highly educated scientists.14 However, focusing
on patents in isolation may misrepresent the nature of the impact of
universities on the economy.15 The growing number of patent
applications by universities indicates that efforts to commercialize
university inventions have increased dramatically.3 Previous research
showed that university patent activities were often related to
commercialized outputs and that universities, for instance, occupy
leading roles in the development of important pharmaceuticals.2,16,17
The commercialization of IP, indicated by patent-related activities,
is controversial in genetics due to the possible negative effects of
patenting human material, for instance, on the availability of
diagnostics and treatments. Some critics argue that biological material
by definition cannot be patented, because it has always existed in
nature and thus does not constitute an invention but rather a mere
discovery.1 Other scholars argue that the technology would not have
developed if discoveries had not been commercially protected, and
neither would the field of genetic research have increased.18
Additionally, without patents, the increase in knowledge might have
been slower19 Despite this debate, a substantial proportion of the
human genome has already been patented by drug and biotech firms
and research institutions,20,21 thereby raising discussions on the
impact of patents for developing medicines, as researchers may be
constrained in their activities. A famous case is the commercial
company Myriad, which has the rights to commercialize specific
hereditary breast cancer genes.22 For several years now, people have
objected to these patents due to the potential impact on diagnostic
testing.23,24 However, in June 2013, the Supreme Court decided in the
Myriad case that human genes, defined as genomic DNA, are not
patentable.25-27
To better understand the trends in GPAs, we studied by whom,
when and where patent applications were filed. We used the
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International Patent Classification (IPC) to collect patent applications
filed with the World Intellectual Property Organization (WIPO) and
the European Patent Office (EPO), using the European version of the
patent classification (ECLA). Previous research observed growth in
US-based genetic patents and GPAs up to the year 2000 and provided
various explanations for this pattern. These explanations include the
end of the human genome project and unprecedented growth in
large-scale sequencing around 200022,28 and new guidelines within the
US Patent and Trademark Office (USPTO).5 We studied time trends
between 1990 and 2009 and explored geographic distribution trends
on four different levels: international, per continent, per country,
and per university in one country (The Netherlands). In this period,
much human and financial investments were made in genetic
research.28-30
MATERIALS AND METHODS
Patent selection
GPAs are those patent applications containing at least one genetic-based term,
for example, nucleic acids, genetic material, mutation or genetic engineering
(as specified in the supplementary data). This means that we include not only
human GPAs but also genetic modifications in plants, fungi, bacteria or
animals. The patent applications that apply are EP (an application filed at the
EPO) and PCT applications (an application filed at WIPO under the Patent
Cooperation Treaty (PCT)). A benefit of using EP and PCT patent application
data is the possibility to compare data across countries, as other metrics often
lack this ability of international comparison. The study’s analysis was done by
using the European version (ECLA) of the IPC and choosing specific
classification numbers with genetic terms in the description, for example:
‘C12N 1/11; modified by introduction of foreign genetic material’ and ‘A61K
31/712; nucleic acids or oligonucleotides having modified sugars, that is, other
than ribose or 20-deoxyribose’ (Source: WIPO Statistics Database, August
2011). We did not use additional keywords. The entire search algorithm and
the list of used patent classifications are attached as Supplementary
Information. In the ECLA and IPC code system, as older patents are updated
to reflect newer classifications, reclassifications in the ECLA or IPC system do
not affect our analysis.
The time period investigated ranged from 1990 until 2009. The data
collection was carried out in PATSTAT – also known as the EPO Worldwide
Statistical Database – using the selected ECLA codes. The patent application
data collected in PATSTAT consisted of published patent application families,
where a patent application family is a set of patent applications from various
countries that originate from the same first filing and usually protect a single
invention.23 Our study thus considers published ‘international’ patent
applications, which consist of the sum of the PCT- and EP-published patent
application families. A limitation of using EP and PCT patent applications is
that this excludes published national and regional patent applications and
patent applications that are not published. As a consequence, patent families
that do not include published PCT or EP patent applications are not covered.
The geographic distribution of GPAs was studied on the international level, by
continent of the applicant, by country of the applicant, and among different
universities. To explore the differences between universities at a national level,
The Netherlands was selected as a typical country.
To analyze the data, the following software and databases were used: Patent
Database Espacenet, Epoline patent register, Epoque database, PATSTAT,
National Centre of Biotechnology Information (NCBI), Pubmed, and Google
Scholar. We tested the data using a multiple linear regression.
RESULTS
The GPAs on the international level, in different continents, countries,
and universities were explored by using PATSTAT and the Espacenet
worldwide database between 1990 and 2009, covering patent applica-
tions filed within the PCT and EP systems (patent applications that
are only filed nationally are not included). Key findings from the
longitudinal analysis of GPAs between 1990 and 2009 are shown in
Figures 1–4.
In the period from 1990 until 2009, the number of patent
applications filed internationally increased (Figure 1). The filing of
international patent applications increased in a linear fashion until in
2009 around 152 000 patent applications were filed. GPAs have
increased as well, although not linearly. As can be seen in Figure 1,
there was a peak in GPAs in 2000. From 1990 to 2009, the
international growth rate of GPAs is about 276%, whereas in the
same period the total patent application growth rate is 794%. The
S&P 500 stock market index, indicating the economic climate, showed
the same pattern as the GPAs until 2003.
To analyze continent-specific patterns, Figure 2 shows the number
of GPAs per continent. Compared with 2000, North America and
Europe experienced a decrease in GPAs of 50%. Although the totals
are relatively low compared with North America and Europe, it is still
interesting to note that after 2000 an increase can be seen for the
continents of South America and Africa, while in Asia the annual
number after 2000 is more or less stable (41000 per year) and
Australia (100–170 per year). Continental differences are observed,
which might be explained by the growing economies in non-Western
countries and changes in legislation and procedures like the European
regulation on legal protection of biotechnological inventions.
Figure 3 shows country-specific patterns of nine countries, which
together account for 98.9% of the total number of GPAs between
1990 and 2009. The United States is responsible for 53.3% of the
GPAs filed internationally within the EP and PCT systems and China
for 2.4%. Most countries, including the United States and China,
show a peak at or around the year 2000. In the case of China, this
increase in 2000 was due to two companies and might be related to
political change and economic development. Biowindow Gene
Development Inc., Shanghai, China filed 22 applications in 1990,
260 applications in 2000, and 1 application in 2001. Biodoor Gene
Technology Ltd., Shanghai, China has no applications in 1990, 59 in
2000, and no applications in 2001.
The classification of the patent applications made it possible to
identify broader technological areas in which GPAs are applied for, to
explore whether or not there was any variation over time in different
technological areas to explain the peak in 2000. Distinguishing five
technology areas (Biotechnology 65%, Pharmaceuticals 18.5%,
Measurement 7.1%, Organic fine chemistry 3.5%, and Food chemistry
1.7%, which account for495% of all GPAs) showed similar patterns
in different technology areas (data not shown).
Figure 1 Total number of patent applications, genetic patent applications
and S&P 500 values from 1990 to 2009.
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Our results at the national level, focusing on The Netherlands, show
important differences between research institutions. The Netherlands
has approximately 2400 international GPAs in the period between
1990 and 2009. The entities with 45 GPAs were divided between
private/industry and public research institutions (government,
universities, research institutes, and hospitals). Private institutions
applied for 73.3% of the GPAs, and public institutions are responsible
for 26.7% of the GPA. There was a significant increase in the number
of GPAs by the Dutch universities between 1990 and 2009 (multiple
regression results: P¼ 0.000, F¼ 44.834, R2¼ 0.714). A peak can also
be seen in The Netherlands in 2000. Compared with 2000, there was a
decrease of 38.6% in GPAs in 2001. Figure 4 shows the total number
of GPAs, which shows large differences between Dutch universities.
The numbers of GPAs are specified for the Dutch universities with
45 GPAs, which is why the three Dutch technology universities are
not shown in the overview. With regard to the Dutch public
institutions, 85.5% of the public GPAs originate from the Dutch
universities.
DISCUSSION
The aim of this paper was to provide insights into the trends of GPAs,
with a focus on patent application trends between 1990 and 2009 on
the international level, per continent, per country, and at Dutch
universities. In comparing the growth in GPAs to the overall growth
of patent applications, genetic patenting showed an unparalleled
growth till 2000 (Figure 1). The literature provides different explana-
tions for the increase of patenting activities in biosciences and
engineering. The first explanation for the increase in the number of
GPAs until 2000 can be found in the investments related to the
sequencing of the human genome as well as the large perceived
market opportunities for some bioscience engineering products.28,31
The second explanation might be the financial support provided by
the biotechnology and pharmaceuticals industries, which led to a
direct increase in commercialization outcomes, with an incidental
effect of the possibility to patent genomic-based inventions.28,29
Since 1980, it has been allowed to patent life forms in the US, and
patenting inventions that used life forms was already possible long
before then. Shortly after many patents applications on genetics were
filed, an influential public debate ensued and several governments (eg,
the Bush Administration) also took action to influence the direction
of genetic research activities.22 Soini et al5 engaged in a dialogue on
patenting and licensing in genetic testing, including ethical, legal, and
social issues, and summarized developments in the previous decades.
James Watson argued: ‘human genes are unique and convey
information about the essences of being human, they should not be
patented, the human genome project was intended to benefit all, not
just select companies, and finally, patents on human genes are not
necessary, but if the are granted, compulsory licenses should be
required to ensure fair access’.32 The European ‘directive on the legal
protection of biotechnological inventions’ (EU/98/44), published in
1998,8 stipulated that the simple discovery of the sequence or partial
sequence of a gene is not considered patentable. However, an element
isolated from the human body or produced by means of a technical
process, including the sequence or partial sequence of a gene, may
constitute a patentable invention. Moreover, in 2001 an important
adjustment was made to patent regulations in the US, which stated
that patent applications for DNA sequences had to explain the
function of the DNA sequence that was to be patented (USPTO).
To explain the decrease in GPAs after 2000, Lawrence33 pointed
to the fact that the Human Genome Project was completed. The
decrease in GPAs took place after the increase of concerns voiced in
the public debate, for instance, in the United States in 2001 when the
New York Times wrote about patents on genetically engineered seeds
and initiated a public discussion on genetic patenting.34 The
discussion about genetic patents and GPAs continues in the
literature.5,22,35 The patentability of a DNA sequence, individual
mutations, SNPs, and gene variants became controversial, as
opposed to patents on a diagnostic test or therapeutic protein.5
The United States is responsible for the greater part of the 2000
peak, as more than half of the international GPAs originate from
there. However, similar patterns were also found in Europe. An
explanation for continental differences may be the difference in patent
strategies of applicants or patent examiners. Different examination
approaches of the patent offices in Europe and the United States
Figure 2 Trends in GPAs per continent.
Figure 3 Trends in GPAs in nine countries.
Figure 4 Total number of GPAs by Dutch Universities, 1990–2009.
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could explain the current legal status of some genetic diagnostic-
testing patent applications.22,23 An additional explanation may be the
differences in economies, like the increased investments in genomics
in the nineties and the possibility to patent genes that made it more
interesting for the industry to invest in genomics. Moreover, Asia and
South America are rapidly developing economies, while in the western
economies after 2000 many investors lost their confidence in the
biotech sector (see in Figure 1 the identical patterns of the S&P500
and the GPAs), which in turn can explain a decrease in international
patent applications and GPAs.
At the country level, just nine countries are responsible for 98.9%
of international GPA filings (Figure 3). Important differences are
observed between these nine countries, which likely are related to
differences in laws and economic variation. The data of nine
international patent applications originating from China shows that
a few individual applicants can create a large shift in the country-level
patterns.
Regarding the national level, Cook-Deegan and Heaney22 observe
that in the United States 39% of the granted DNA patents are owned
by academic institutions (in the period 1980–1993), which is relatively
high, as for the total of patents the percentage from academic
institutions is only 5%. This might partly be explained by the fact
that genetic research was relatively important at universities, com-
pared with older technologies. Biotech researchers in universities
found that unlike researchers in other sciences their research results
had the potential to be both patentable and profitable. Universities
with such departments therefore became active in filing patent
applications. Universities were encouraged to set up TTOs and file
applications, for instance, by governments, governing bodies, and law
changes. In The Netherlands, 26.7% of the international GPAs are
from the public research institutions, 85.5% of which are from
universities. Large differences in the number of GPAs exist among
Dutch universities (Figure 4). Leiden University would appear to be
leading in patent applications, with especially the Clinical Genetics
Centre and their head of the Department of Human Genetics
(Professor GB van Ommen) filing many patent applications.
Researchers who are the head of a department in combination with
top research positions appear to have the most patent applications to
their name in the field of genetics. Other examples of such researchers
are Rene Bernards from The Netherlands Cancer Institute (NKI),
Frank Grosveld, Chair of Cell Biology at the Erasmus University
Rotterdam, and Mathieu Noteborn, Professor in Molecular Genetics
at Leiden University. The patenting activity of one single professor
and one research centre are thus the main driving forces behind the
observed pattern. These results are consistent with the role of
leadership described in a study by Bercovitz and Feldman,36 which
explains that the chair of the department has an influence on the
commercialization of IP. The chair’s activities will have an effect on
other members of the department, stimulating them to become more
involved in patenting as well.36,37 Thus, the observed differences
between universities might be explained on a micro level by
differences among research group leaders within universities as well
as by differences in technology transfer-support infrastructures.31,38
Three studies described trends in genetic patents in the past, using
a method different from ours, for example, by looking at published
patents instead of published patent applications; results from these
studies show similarities as well as differences when compared with
our findings.22,39,40 Oldman40 searched for trends in patent claims in
genomics, proteomics, and biotechnology by using keywords in the
Espacenet titles such as genes, proteins, DNA, amino acids, nuclide
nucleic acids, and RNA in the time period 1990–2003. Unfortunately,
as this study used a different method the results are difficult to
compare. Nevertheless, the result showed a peak in published patents
around 2002, which indicates a peak in patent applications in 2000.
Cook-Deegan and Heaney22 investigated granted US patents using the
Delphion Patent Database based on the USPTO classification system
and considered the time frame 1984–2008. The analysis of US DNA
patents by Cook-Deegan and Heaney22 also shows a peak, although it
is less pronounced and somewhat later, around 2001. A possible
explanation for the different pattern is that Cook-Deegan and
Heaney22 use a different database and an algorithm that searches
for granted US patents rather than published patent applications,
which appears to result in a different trend, as it is difficult to
compare patent applications with granted patents. Oldman and Hall39
also investigated patent applications, using the same method as our
study (PATSTAT), which resulted in a similar trend in total patent
applications. However, they used different genetic/biotech IPC codes
(including biotechnology in a broad sense), which resulted in GPA
figures that could not be compared.
Limitations
This study is not without its limitations. First of all, the register of
patent data unavoidably contains some errors, such as mis-spellings of
author or institution names (eg, verengning vu-windesheim). Second,
the choice by a patent examiner of a specific IPC number defines
whether a patent application is considered as a genetic patent
application or not, while this category might also include patent
applications that have barely any genetic content and could also
exclude patent applications that may be related to genetics. Third, our
choice of IPC numbers defines which patent applications we consider
as being related to genetics. Others might choose a more restricted
selection, as applications for a patent on a gene are just a fraction of
the applications that were revealed in our search. Fourth, some patent
applications have more than one IPC number, including only one of a
few genetic code numbers, which implies that sometimes other
characteristics than ‘genetic’ might characterize the application better.
Therefore, some patent applications might be less related to genetics
than that appears from the IPC numbers. These limitations may
influence the results. Finally, this study focused on patent applications
within the international EP and PCT systems to enable meaningful
comparisons between countries and continents. Also including
national-only filings as well might generate different patterns, in
particular with regard to the United States and China.
CONCLUSIONS
Since 1990, the number of international GPAs increased up to 2000
and declined by 50% thereafter. The peak is seen in the United States
and Europe, while Asia shows a stable level, and Africa and Australia
show a small but gradual increase. Nine countries together account
for 98.9% of GPAs. Public institutions and universities have applied
for relatively many genetic patents. One or several leaders within an
institution can strongly influence trends in GPAs. Finally, the ongoing
investments in genetic research after 2000 are not reflected in an
increase in the number of GPAs.
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